B3 agonists or anticholinergics in the treatment of the lower urinary tract dysfunction in patients with multiple sclerosis?-A randomized study.
Acetanilides
/ administration & dosage
Adrenergic beta-3 Receptor Agonists
/ administration & dosage
Cholinergic Antagonists
/ administration & dosage
Drug Monitoring
/ methods
Female
Humans
Lower Urinary Tract Symptoms
/ diagnosis
Male
Middle Aged
Multiple Sclerosis
/ diagnosis
Single-Blind Method
Symptom Assessment
/ methods
Thiazoles
/ administration & dosage
Treatment Outcome
Ultrasonography
/ methods
Anticholinergics
Lower urinary tract dysfunction
Multiple sclerosis
b3 agonists
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
30
10
2020
accepted:
05
12
2020
pubmed:
3
1
2021
medline:
11
1
2022
entrez:
2
1
2021
Statut:
ppublish
Résumé
Multiple sclerosis (MS) is the most frequent autoimmune demyelinating disease of the central nervous system. MS patients usually present with lower urinary tract dysfunction (LUTD). Objective of this study is to evaluate and compare the efficacy and safety of treating MS patients with LUTD with either a b3 agonist (mirabegron) or anticholinergics. The study's primary outcome is the LUTD symptom improvement. This is a multi-center, single-blinded, comparative study including 91 MS patients with LUTD. At baseline, patients underwent thorough clinical examination, urine cultivation and abdominal ultrasound and completed urination diaries and specific, validated questionnaires (NBSS, MusiQoL). At second visit, patients were administered either mirabegron or anticholinergics. Treatment was always carried out alongside with MS treatment. Reevaluation was performed 3 months after first visit. Patients underwent the same clinical and imaging tests that were carried out at first visit. We compared several clinical and imaging parameters between the two groups at first visit and month 3 after treatment. Νo statistical difference was noted between the mirabegron group and the anticholinergic group in terms of LUTD improvement. In both groups, improvement from baseline regarding LUTD was recorded. Statistical analysis was performed using the paired and unpaired t test method. No patient discontinued either medication due to side effects. MS patients receiving either mirabegron or anticholinergic therapy for LUTD showed improvement. Nevertheless, no statistical difference was noted between the two cohorts at 3 months in terms of drug efficacy in all the statistically significant parameters.
Identifiants
pubmed: 33386947
doi: 10.1007/s00345-020-03555-8
pii: 10.1007/s00345-020-03555-8
doi:
Substances chimiques
Acetanilides
0
Adrenergic beta-3 Receptor Agonists
0
Cholinergic Antagonists
0
Thiazoles
0
mirabegron
MVR3JL3B2V
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
3049-3056Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
Références
Phé V, Chartier-Kastler E, Panicker JN (2016) Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol 13(5):275–288
doi: 10.1038/nrurol.2016.53
Aharony S, Lam O, Corcos J (2017) Treatment of lower urinary tract symptoms in multiple sclerosis patients: review of the literature and current guidelines. Can Urol Assoc J 11(1–2):61–64
doi: 10.5489/cuaj.4058
Panicker JN, Fowler CJ, Kessler TM (2015) Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol 14:720–732
doi: 10.1016/S1474-4422(15)00070-8
Ruffion A, Castro-Diaz D, Patel H et al (2013) Systematic review of the epidemiology of urinary incontinence and detrusor overactivity among patients with neurogenic overactive bladder. Neuroepidemiology 41:146–155
doi: 10.1159/000353274
Yang CC (2013) Bladder management in multiple sclerosis. Phys Med Rehabil Clin N Am 24(4):673–686
doi: 10.1016/j.pmr.2013.06.004
Poser CM, Paty DW, Scheinberg L et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13(3):227–231
doi: 10.1002/ana.410130302
McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127
doi: 10.1002/ana.1032
Simeoni M, Auquier P, Fernandez O et al (2008) Validation of the multiple sclerosis international quality of life questionnaire. MultScler 14(2):219–230
Welk B, Morrow S, Madarasz W et al (2014) The validity and reliability of the neurogenic bladder symptom score. J Urol 192(2):452–457
doi: 10.1016/j.juro.2014.01.027
Triantafyllou N, Triantafyllou A, Tsivgoulis G (2009) Validity and reliability of the Greek version of the multiple sclerosis international quality-of-life questionnaire. J ClinNeurol 5(4):173–177
Tzelves L, Glykas I, Fragkoulis Ch et al (2020) Validity and reliability of the Greek version of the neurogenic bladder symptom score (NBSS) questionnaire in a sample of Greek patients with multiple sclerosis. World J Urol. https://doi.org/10.1007/s00345-020-03465-9
doi: 10.1007/s00345-020-03465-9
pubmed: 32986135
Madhuvrata P, Singh M, Hasafa Z et al (2012) Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and metaanalysis. Eur Urol 62:816–830
doi: 10.1016/j.eururo.2012.02.036
Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383
doi: 10.1016/0021-9681(87)90171-8
Nicholas RS, Friede T, Hollis S et al (2009) Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev 1:CD004193
Amarenco G, Sutory M, Zachoval R et al (2017) Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourol Urodyn 36(2):414–421
doi: 10.1002/nau.22945
Goodson AB, Cantrell MA, Shaw RF et al (2018) Comparative effectiveness of anticholinergic agents for lower urinary tract symptoms. J Manag Care Spec Pharm 24(1):65–72
pubmed: 29290176
Cameron AP (2010) Pharmacologic therapy for the neurogenic bladder. Urol Clin North Am 37:495
doi: 10.1016/j.ucl.2010.06.004
Tornic J, Panicker JN (2018) The management of lower urinary tract dysfunction in multiple sclerosis. CurrNeurolNeurosci Rep 18(8):54
De Ridder D, Van Der Aa F, Debruyne J et al (2013) Consensus guidelines on the neurologist’s role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis. Clin Neurol Neurosurg 115:2033–2040
doi: 10.1016/j.clineuro.2013.06.018
Andersson K-E (2014) Current and future drugs for treatment of MS- associated bladder dysfunction. Ann PhysRehabil Med 57:321–328
Bragg R, Hebel D, Vouri SM et al (2014) Mirabegron: a beta-3 agonist for overactive bladder. Consult Pharm 29(12):823–837
doi: 10.4140/TCP.n.2014.823
Wagg A, Nitti VW, Kelleher C et al (2016) Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin 32(4):621–638
doi: 10.1185/03007995.2016.1149806
Sebastianelli A, Russo GI, Kaplan SA (2018) Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: comparison with placebo and tolterodine. Int J Urol 25(3):196–205
doi: 10.1111/iju.13498
Kelleher C, Hakimi Z, Zur R et al (2018) Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. EurUrol 74(3):324–333
Krhut J, Borovička V, Bílková K et al (2018) Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn 37(7):2226–2233
doi: 10.1002/nau.23566
Welk B, Hickling D, McKibbon M et al (2018) A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourol Urodyn 37(8):2810–2817
doi: 10.1002/nau.23774
Zachariou A, Filiponi M, Baltogiannis D et al (2017) Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron. Can J Urol 24(6):9107–9113
pubmed: 29260636
Brucker BM, Jericevic D, Rude T et al (2020) Mirabegron versus solifenacin in multiple sclerosis patients with overactive bladder symptoms: a prospective comparative nonrandomized study. Urology 9:30998
El Helou E, Labaki C, Chebel R et al (2019) The use of mirabegron in neurogenic bladder: a systematic review. World J Urol 5:7
Glykas I, Fragkoulis Ch, Mitsikostas DD et al (2019) Is there a role for b3 agonists or anticholinergics in the treatment of the lower urinary tract symptoms in patients with multiple sclerosis? Hell Urol 1:26–32